Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
An update from Shanghai Junshi Biosciences Co., Ltd. Class H ( (HK:1877) ) is now available.
Shanghai Junshi Biosciences has disclosed that it previously obtained board approval to use up to RMB2 billion of idle fundraising proceeds to temporarily supplement working capital for up to 12 months. The funds were restricted to business expansion, daily operations and production activities related to its core pharmaceutical business, with an obligation to return them to a dedicated proceeds account as project funding needs arose.
Under this mandate, the company deployed approximately RMB1.106 billion of idle proceeds to bolster liquidity within the specified period, enabling more flexible cash management. Management stated that this internal financing arrangement was reasonably arranged and did not disrupt the normal progress of investment projects backed by the original fundraising, suggesting a controlled approach to balancing liquidity needs with long-term R&D and expansion plans.
The most recent analyst rating on (HK:1877) stock is a Hold with a HK$22.50 price target. To see the full list of analyst forecasts on Shanghai Junshi Biosciences Co., Ltd. Class H stock, see the HK:1877 Stock Forecast page.
More about Shanghai Junshi Biosciences Co., Ltd. Class H
Shanghai Junshi Biosciences Co., Ltd. is a China-based biopharmaceutical company focused on the research, development and commercialization of innovative medicines. Listed in both Shanghai and Hong Kong, it develops therapies tied to its principal business and funds related investment projects through dedicated proceeds accounts.
Average Trading Volume: 3,181,226
Technical Sentiment Signal: Sell
Current Market Cap: HK$32.51B
For a thorough assessment of 1877 stock, go to TipRanks’ Stock Analysis page.